SCHEMBL67583

SCHEMBL67583

CC(C)(C)c1[nH]cnc1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.46
CYP1A2 P05177 1/20 0.46
CDK1 P06493 1/20 0.46
CYP2C9 P11712 1/20 0.46
CCNB1 P14635 1/20 0.46
CYP2C19 P33261 1/20 0.46
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40
TUBB2A Q13885 2/20 0.40
TUBB8 Q3ZCM7 2/20 0.40
TUBA3E Q6PEY2 2/20 0.40
TUBA1A Q71U36 2/20 0.40
TUBA1C Q9BQE3 2/20 0.40
TUBB6 Q9BUF5 2/20 0.40
TUBB2B Q9BVA1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21050025 0.83 CYP1A2 (0.48) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL66212 0.83 KDM4E (0.50) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL80769 0.78 RAF1 (0.43) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL21276637 0.74 RAF1 (0.38) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL632905 0.73
SCHEMBL25046297 0.71 KDM4E (0.50) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL1509437 0.70
SCHEMBL12244444 0.70 HPGD (0.36) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL21718551 0.68 TUBB4A (0.39) RAF1CYP1A2CDK1CYP2C9CCNB1
SCHEMBL21719515 0.68 CDK2 (0.35) RAF1CYP1A2CDK1CYP2C9CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4089085-B1 MANUFACTURING AND PURIFICATION METHOD OF POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND SHENZHEN HUAHONG MARINE BIOMEDICINE CO LTD (CN) 2024-04-03 EP claimed
US-11608325-B2 Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof Shenzhen Huahong Marine Biomedicine Co., Ltd. (CN) 2023-03-21 US claimed
EP-4089085-A1 MANUFACTURING AND PURIFICATION METHOD OF POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND Shenzhen BGI Marine Sci & Tech Co., Ltd (CN) 2022-11-16 EP claimed
CN-109580801-A A kind of high performance liquid chromatography detecting Antitubulin and related impurities 深圳海王医药科技研究院有限公司 2019-04-05 CN claimed
CN-119330935-A Salt of plinabulin and use thereof 成都施贝康生物医药科技有限公司 2025-01-21 CN disclosed
EP-4089085-B1 MANUFACTURING AND PURIFICATION METHOD OF POLYCRYSTALLINE FORM OF DEHYDROPHENYLAHISTIN-LIKE COMPOUND SHENZHEN HUAHONG MARINE BIOMEDICINE CO LTD (CN) 2024-04-03 EP disclosed
CN-117510476-A Plinabulin derivative, preparation method and application thereof 中国科学院长春应用化学研究所 2024-02-06 CN disclosed
CN-117285516-A Dehydrogenated phenyl achyranthis statin compound, preparation method and application thereof 大连万众益生大健康有限公司 2023-12-26 CN disclosed
CN-114276332-B Polymorphic form of dehydrogenated phenyl-achyranthes and its preparing and purifying process and application 深圳华大海洋科技有限公司 2023-08-18 CN disclosed
CN-116496257-A Pranabulin prodrug, preparation method and application thereof 成都施贝康生物医药科技有限公司 2023-07-28 CN disclosed
US-11608325-B2 Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof Shenzhen Huahong Marine Biomedicine Co., Ltd. (CN) 2023-03-21 US disclosed
US-11578057-B2 Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof Shenzhen Huahong Marine Biomedicine Co., Ltd. (CN) 2023-02-14 US disclosed
US-20060217553-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof NEREUS PHARMACEUTICALS, INC. 2006-09-28 US disclosed
US-7064201-B2 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof NEREUS PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
CN-1684955-A Dehydrophenylahistine and analogs thereof and synthesis of dehydrophenylahistine and analogs thereof NEREUS PHARMACEUTICALS INC (US) 2005-10-19 CN disclosed
US-20050197344-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof BEYONDSPRING PHARMACEUTICALS, INC. 2005-09-08 US disclosed
WO-2005077940-A1 DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF NEREUS PHARMACEUTICALS, INC. (US) 2005-08-25 WO disclosed
EP-1529044-A2 DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF Nereus Pharmaceuticals, Inc. (US) 2005-05-11 EP disclosed
US-20050090667-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof BEYONDSPRING PHARMACEUTICALS, INC. 2005-04-28 US disclosed
WO-2004054498-A2 DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF NEREUS PHARMACEUTICALS, INC. (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217553-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof TPD52L2, DHPS, DCXR RAF1 2336/4885CYP1A2 464/4885CDK1 465/4885
US-20050090667-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof TPD52L2, DHPS, DCXR RAF1 2336/4885CYP1A2 464/4885CDK1 465/4885
US-11608325-B2 Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof DHPS, HDHD5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 RAF1 1372/4885CYP1A2 1849/4885CDK1 2739/4885
US-20050197344-A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof DHFR, DHPS, QDPR RAF1 2807/4885CYP1A2 951/4885CDK1 418/4885
US-11578057-B2 Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof DHPS, HDHD5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 RAF1 1463/4885CYP1A2 1798/4885CDK1 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.